¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"TATA-Binding Protein Associated Factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • foreign protein
    ÀÌÁ¾´Ü¹éÁú
  • glial fibrillary acidic protein
    ¾Æ±³¼¼Æ÷¼¶À¯»ê¼º´Ü¹éÁú, ±³¼¶À¯»ê¼º´Ü¹éÁú
  • globular protein
    °ø¸ð¾ç´Ü¹éÁú, ±¸»ó´Ü¹éÁú
  • heat-shock protein
    ¿­Ãæ°Ý´Ü¹éÁú
  • heterologous protein
    ÀÌÁ¾´Ü¹éÁú
  • high-protein diet
    °í´Ü¹éÁú½Ä»ç
  • human plasma protein fraction
    »ç¶÷Ç÷Àå´Ü¹éºÐÀ²
  • iron binding protein
    ö°áÇմܹéÁú
  • major basic protein
    ÁÖ¿ä±âÃʴܹéÁú, ÁÖ±âÀú´Ü¹éÁú
  • mitogen-activated protein kinase
    ¹ÌÅä°ÕȰ¼ºÈ­´Ü¹éÁúŰ³ª¾ÆÁ¦
  • monocyte chemotactant protein
    ´ÜÇÙ±¸È­Çнò¸²´Ü¹éÁú, ´ÜÇÙ±¸È­ÇÐÁÖ¼º´Ü¹é
  • matrix protein
    ¹ÙÅÁÁú´Ü¹éÁú
  • membrane control protein
    ¸·Á¶Àý´Ü¹éÁú
  • olfactory binding protein
    Èİ¢°áÇմܹéÁú
  • oligomeric protein
    ¿Ã¸®°í¸Ó´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • protein granule
    ´Ü¹éÁú°ú¸³
  • heat-shock protein
    ¿­Ãæ°Ý´Ü¹é
  • heterologous protein
    ÀÌÁ¾´Ü¹é
  • iron binding protein
    ö°áÇմܹéÁú
  • protein bound iodine
    ´Ü¹éÁú°áÇÕ¿ä¿Àµå
  • mitogen-activated protein kinase
    ºÐ¿­Á¦È°¼º´Ü¹éŰ³ª¾ÆÁ¦
  • protein kinase
    ´Ü¹éÁúŰ³ª¾ÆÁ¦
  • protein layer
    ´Ü¹éÁúÃþ
  • major basic protein
    ÁÖ±âÀú´Ü¹é, ÁÖ¿ä±âÃʴܹé
  • matrix protein
    ¹ÙÅÁÁú´Ü¹é
  • membrane control protein
    ¸·Á¶Àý´Ü¹é
  • monocyte chemotactant protein
    ´ÜÇÙ±¸È­Çнò¸²´Ü¹é, ´ÜÇÙ±¸È­ÇÐÁÖ¼º´Ü¹é
  • olfactory binding protein
    Èİ¢°áÇմܹé
  • oligomeric protein
    ¿Ã¸®°í¸Ó´Ü¹éÁú
  • protein
    ´Ü¹é, ´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • PPD(Purified protein derivative) test
    PPD °Ë»ç.
  • Reiters protein
    ¶óÀÌÅÍ ¸Åµ¶Áø´Ü¿ë´Ü¹éÁú
  • S100 protein
    S100 ´Ü¹éÁú
  • actin-binding protein
    ¾×ƾ °áÇմܹé(¡­Ì¿ùêÓ±ÛÜ)
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
  • activated protein C resistance
    Ȱ¼ºÈ­C´Ü¹é³»¼º
  • acute phase protein
    ±Þ¼ºº´±â´Ü¹éÁú
  • acute phase reactive protein
    ±Þ¼º±â ¹ÝÀÀ¼º ´Ü¹é.
  • amyloid precurssor protein
    ¾Æ¹Ð·ÎÀ̵å Àü±¸ ´Ü¹éÁú
  • androgen- binding protein
    ¸¸¼ºÈ£¸£¸ó °áÇմܹé
  • anion exchange protein
    À½À̿ ±³È¯ ´Ü¹é(ÎßüµÓ±ÛÜ)
  • antifreeze protein
    Ç×µ¿°á´Ü¹éÁú(ù÷ÔÐÌ¿ Ó±ÛÜòõ).
  • ganglioside activator protein
    °»±Û¸®¿À»çÀ̵å Ȱ¼º´Ü¹éÁú
  • glial fibrillary acidic protein
    ½Å°æ±³¿ø¼¶À¯(Îïê«àéë«)»ê(ß«)´Ü¹é
  • globular protein
    ±¸»ó´Ü¹é(Áú)(¡­Ó±ÛÜòõ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mucosa-associated lymphoid tissue
    Á¡¸·¿¬°ü¸²ÇÁÁ¶Á÷(¡­æáμ¡­ðÚòÄ)
  • mucous associated lymphoid tissue (MALT)
    Á¡¸· ¿¬°ü¼º ¸²ÇÁÁ¶Á÷
  • nucleolus associated chromatin
    ÇÙ¼ÒüºÎÂø¿°»öÁú(ú·á³ô÷Ý¾ó·æøßäòõ).
  • skin-associated lymphoid tissue (SALT)
    ÇǺο¬°ü ¸²ÇÁÁ¶Á÷°è
  • tumor associated antigen
    Á¾¾ç°ü·ÃÇ׿ø
  • tumor associated rejection antigen
    Á¾¾ç°ü·Ã°ÅºÎÇ׿ø
  • tumor-associated antigen
    Á¾¾ç°ü·ÃÇ׿ø
  • actin-binding protein
    ¾×ƾ °áÇմܹé(¡­Ì¿ùêÓ±ÛÜ)
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
  • activated protein C resistance
    Ȱ¼ºÈ­C´Ü¹é³»¼º
  • acute phase protein
    ±Þ¼ºº´±â´Ü¹éÁú
  • acute phase reactive protein
    ±Þ¼º±â ¹ÝÀÀ¼º ´Ü¹é.
  • al protein
    AL ´Ü¹é(¡­Ó±ÛÜ)
  • amyloid precurssor protein
    ¾Æ¹Ð·ÎÀ̵å Àü±¸ ´Ü¹éÁú
  • androgen- binding protein
    ¸¸¼ºÈ£¸£¸ó °áÇմܹé
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • carrier protein
    ¿î¹Ýü´Ü¹éÁú(ê¡Úæô÷Ó±ÛÜòõ)
  • catabolite activator protein
    īŸº¼¶óÀÌÆ® Ȱ¼ºÈ­ ´Ü¹éÁú(üÀàõûùÓ±ÛÜòõ)
  • cell-free protein synthesis
    ¹«¼¼Æ÷´Ü¹éÁúÇÕ¼º(Ùíá¬øàÓ±ÛÜòõùêà÷)
  • cellular retinol-binding protein
    ¼¼Æ÷(á¬øà) ·¹Æ¼³î°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ)
  • channel protein
    ä³Î ´Ü¹éÁú(Ó±ÛÜòõ)
  • chimeric protein
    Ű¸Þ¶ó ´Ü¹éÁú(Ó±ÛÜòõ)
  • cholesterol ester transfer protein
    ÄÝ·¹½ºÅ×·Ñ¿¡½ºÅÍ ÀüÀ̴ܹéÁú(ï®ì¹Ó±ÛÜòõ)
  • coat protein
    ¿ÜÇǴܹéÁú(èâù«Ó±ÛÜòõ)
  • competitive protein-binding technique
    °æÇÕÀû ´Ü¹éÁú °áÇÕ¼ú(ÌæùêîÜÓ±ÛÜòõÌ¿ùêâú)
  • complete protein
    ¿ÏÀü´Ü¹éÁú(èÇîïÓ±ÛÜòõ)
  • conjugated protein
    Á¢ÇմܹéÁú(ïÈùêÓ±ÛÜòõ)
  • contractile protein
    ¼öÃ༺ ´Ü¹éÁú(â¥õêàõÓ±ÛÜòõ)
  • copper protein
    µ¿´Ü¹éÁú(ÔÞÓ±ÛÜòõ)
  • core protein
    ÇٽɴܹéÁú(ú·ãýÓ±ÛÜòõ)
  • corticosteroid-binding protein
    "ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ), (ÔÒ) transcortin"
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PF1-4 platelet factors 1 to 4
PQRST provocative and palliative factors, quality of pain, radiation of pain, severity of pain, timing of ...
PULSES physical condition, upper limb function, lower limb function, sensory component, excretory function,...
GAP D-glyceraldehyde-3-phosphate; growth associated protein; guanosine triphosphatase-activating protein...
SAP sensory action potential; serum acid phosphatase; serum alkaline phosphatase; serum amyloid P; situs...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HGF Hemopoietic growth factors
HBGF Heparin binding growth factors
IGFBPs Insulin-like growth factors and their binding proteins
IGF-II Insulin-like growth factors I and II
MRF Monoclonal rheumatoid factors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • plasma protein
    Ç÷Àå ´Ü¹é, Ç÷Àå ´Ü¹éÁú
    1. Ç÷Àå¿¡ Á¸ÀçÇÏ´Â ¿©·¯ Á¾·ùÀÇ ´Ü¹éÁú. ¿î¹Ý ´Ü¹éÁú
  • plasma protein binding
    Ç÷Àå ´Ü¹é °áÇÕ
  • protein
    ´Ü¹éÁú
  • protein bound radioactive iodine
    PBRI
  • protein hydrolysate
    ´Ü¹é ¼öÇØ¹°
    ´Ü¹éÁúÀ» »ê, ¾ËÄ®¸®, È¿¼Ò µîÀ¸·Î ºÐÇØÇÏ¿© »ý±â´Â ¾Æ¹Ì ³ë»êÀÇ È¥ÇÕ¹°·Î, À̰ÍÀ¸·Î ¾ò¾îÁö´Â Á¦Àç´Â ¾Æ¹Ì³ë»ê ¼ººÐÀ¸·Î º¼ ¶§, ¿ø·¡ÀÇ ¹°Áú°ú ¿µ¾çÇÐÀûÀ¸·Î µî°¡·Î¼­, º¸ÅëÀÇ ½ÄÀ̼º ´Ü¹éÀ» ¼·ÃëÇÏÁö ¸øÇϴ ȯÀÚ¿ë ¶Ç´Â Æ¯º°½ÄÀ¸·Î »ç¿ëµÈ´Ù.
  • protein polysaccharide
    ´Ü¹é ´Ù´ç·ù
  • protein-drug complex
    ´Ü¹é-¾à¹° º¹ÇÕü
  • protein-losing gastroenteropathy
    ´Ü¹é »ó½Ç¼º À§ÀåÁõ
  • serum amyloid protein A
    Ç÷û ¾Æ¹Ð·ÎÀ̵å ÇÁ·Îƾ A
  • serum protein
    Ç÷Àå ´Ü¹é
  • serum protein meter
    Ç÷û ´Ü¹é°è
    Ç÷û ´Ü¹é Á¤·®¿ëÀÇ ¼ÒÇü ±¼Àý°è.
  • silver protein mild
    ¾à·Â ÇÁ·ÎÅ×ÀÎ Àº
    Àº 19¡­23%¸¦ ÇÔÀ¯Çϰí, ´Ü¹éÁúÀÇ Á¸Àç ¶Ç´Â ´Ü¹é°úÀÇ °áÇÕ¿¡ ÀÇÇØ¼­ ÄÝ·ÎÀ̵åÈ­ÇÑ Á¦Á¦. ¾Ï°¥»ö ¶Ç´Â °ÅÀÇ Èæ»öÀÇ ºñ´Ã ¶Ç´Â °ú¸³À¸·Î¼­ Á÷Àå, ´«, Áú, ¿äµµ, ±Í, ÄÚ, ¹× ÀεΠµîÀÇ ¿©·¯ °¡Áö °¨¿°Áõ¿¡ ±¹¼Ò¿ë Ç×°¨¿°Á¦·Î »ç¿ëÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
pregnancy-associated esterase <enzyme> In baboons, amount of activity correlates with stage of pregnancy; hydrolyzes alpha-naphthyl butyrate in preference to alpha-naphthyl acetate
Registry number: EC 3.1.1.-
Synonym: pregnancy esterase
(26 Jun 1999)
hepatitis-associated antigen A term used for the surface antigen of hepatitis B virus before its nature was established.
See: hepatitis B surface antigen.
(05 Mar 2000)
scaffold-associated regions Sites in DNA that bind topoisomerase II and other scaffold proteins; found in introns.
(05 Mar 2000)
herpes virus, kaposi sarcoma-associated Species of an unnamed genus, subfamily gammaherpesvirinae, isolated from patients with aids-related and "classical" kaposi sarcoma. The sequences suggest this is a new human herpes virus, unofficially identified as human herpes virus-8 (hhv-8).
(12 Dec 1998)
human leukaemia-associated antigens Antigen's on the surface of leukaemic cells which seem not to be present on the surfaces of the same type of normal cells; the myeloblast antigen of acute myelogenous leukaemia found in chronic myelogenous leukaemia is thought to be associated with a "blastic" transformation.
(05 Mar 2000)
human leukocyte-associated antigens Proteins on the outer part of body cells that help fight illness. These proteins vary from person to person. Scientists think that people with certain types of HLA antigens are more likely to develop insulin-dependent diabetes.The HLA antigens are also responsible for histocompatibility reactions.
(09 Oct 1997)
neurofilament-associated kinase <enzyme> Phosphorylates a subset of peptides in vitro which are phosphorylated in vivo in cultured neurons
Registry number: EC 2.7.1.-
Synonym: naf kinase
(26 Jun 1999)
NS5A-associated kinase <enzyme> Involved in the phosphorylation of the hepatitis c virus ns5a nonstructural protein in vitro and in vivo
Registry number: EC 2.7.10.-
(26 Jun 1999)
Ir associated antigen Antigens coded for by IR (immune response) genes or antigens coded for by the genome close to the IR genes.
See: Ia antigens.
(18 Nov 1997)
I region associated antigens Class II major histocompatibility (MHC) antigens.
(18 Nov 1997)
tat-associated kinase <enzyme> Abbreviated tak; binds to activation domain of tat
Registry number: EC 2.7.1.-
Synonym: p-tefb, positive transcriptional elongation factor b
(26 Jun 1999)
encephalomyelitis associated with carcinoma An encephalomyelopathy as a remote effect of carcinoma, most often oat cell carcinoma of the lung; characterised by extensive nerve cell loss, which may be diffuse, but often predominates in particular portions of the central nervous system, particularly the limbic lobes, medulla, cerebellum, and gray matter of the spinal cord.
Synonym: carcinomatous encephalomyelopathy, encephalomyelitis associated with carcinoma, paracarcinomatous encephalomyelopathy.
(05 Mar 2000)
ergot alkaloid-associated heart disease Heart disease caused by endomyocardial fibrosis which extends into valve structures, producing stenosis and/or regurgitation, associated with ergot alkaloid use.
(05 Mar 2000)
tumour-associated antigen Antigens that are highly correlated with certain tumour cells. They are not usually found, or are found to a lesser extent, on normal cells.
(05 Mar 2000)
Kaposi sarcoma associated herpesvirus protease <enzyme> Genbank af010430
Registry number: EC 3.4.21.-
Synonym: kshv protease, human herpesvirus 8 protease
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á